Investor
Decheng Capital LLC
CIK 0002010850 · filed 2026-05-13 · SEC filing
13F book
$661.3M
Positions
14
0 new · 5 sold
Largest name
65.2%
CG Oncology, Inc. · CGON
Est. mark
−$41.9M
Price effect on 14 names still held. Flow −$40.2M.
| Name | Ticker | Shares | Value | Weight | Est. mark | Change |
|---|---|---|---|---|---|---|
| CG Oncology, Inc. | CGON | 6.37M | $431.2M | 65.2% | $166.7M | Held |
| Nuvation Bio Inc. | NUVB | 26M | $111.3M | 16.8% | −$121.2M | Held |
| Upstream Bio, Inc. | UPB | 2.72M | $24.5M | 3.7% | −$49.5M | Cut−$60.8M |
| Aclaris Therapeutics, Inc. | ACRS | 4.04M | $15.2M | 2.3% | $2.99M | Held |
| Aardvark Therapeutics, Inc. | AARD | 3.92M | $14.8M | 2.2% | −$36.6M | Held |
| Lyell Immunopharma, Inc. | LYEL | 692K | $13.9M | 2.1% | −$7.42M | Held |
| Newamsterdam Pharma Company | — | 325.1K | $10.4M | 1.6% | −$997.9K | Cut−$10.4M |
| Arcus Biosciences, Inc. | RCUS | 477.8K | $10.3M | 1.6% | −$1.07M | Cut−$2.58M |
| Revolution Medicines Inc | — | 93.5K | $9.09M | 1.4% | $1.65M | Cut−$6.84M |
| Equillium, Inc. | EQ | 4.45M | $8.89M | 1.3% | $2M | Held |
| BeyondSpring Inc. | BYSI | 3.8M | $6.23M | 0.9% | $38K | Held |
| Zentalis Pharmaceuticals, Inc. | ZNTL | 1.32M | $3.1M | 0.5% | $1.31M | Held |
| Krystal Biotech, Inc. | KRYS | 7.3K | $1.89M | 0.3% | $86K | Cut−$2.38M |
| Pyxis Oncology, Inc. | PYXS | 326.8K | $477.1K | 0.1% | $101.3K | Held |
Positions as of Q1 2026. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.